Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -6.60% | 123.47 | 0.0% | $1121.14m | |
| OCGN | Ocugen, Inc. | -1.26% | 8.63 | 0.0% | $797.67m | |
| AMGN | Amgen, Inc. | 0.04% | 227.81 | 1.3% | $546.41m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.35% | 463.19 | 2.7% | $534.62m | |
| NVAX | Novavax, Inc. | -9.71% | 157.87 | 92.9% | $533.68m | |
| GILD | Gilead Sciences, Inc. | 0.20% | 64.75 | 1.0% | $502.19m | |
| ILMN | Illumina, Inc. | -3.82% | 383.62 | 3.5% | $481.24m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 0.76% | 213.58 | 1.9% | $461.68m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.03% | 150.06 | 2.0% | $329.21m | |
| BNGO | BioNano Genomics, Inc. | 8.67% | 7.77 | 0.0% | $322.31m | |
| CRSP | CRISPR Therapeutics AG | -0.90% | 113.62 | 0.6% | $321.43m | |
| BIIB | Biogen, Inc. | -0.26% | 270.01 | 1.7% | $296.77m | |
| EXAS | EXACT Sciences Corp. | -4.17% | 116.57 | 18.4% | $244.18m | |
| SGEN | Seagen Inc. | -0.45% | 148.68 | 5.8% | $208.59m | |
| PACB | Pacific Biosciences of California, Inc. | -6.49% | 27.37 | 7.2% | $176.05m |
Company Profile
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.